FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509042913> ?p ?o ?g. }

• W2509042913 endingPage "e0161415" @default.
• W2509042913 startingPage "e0161415" @default.
• W2509042913 abstract "The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little is known about how to combine them in optimal ways. Immunotoxins are antibody-toxin gene fusion proteins engineered to target cancer cells via antibody binding to surface antigens. For fusion proteins derived from Pseudomonas exotoxin (PE), potency relies on the enzymatic domain of the toxin which catalyzes the ADP-ribosylation of EF2 causing inhibition of protein synthesis leading to cell death. Candidate immunotoxins have demonstrated clear value in clinical trials but generally have not been curative as single agents. Therefore we undertook three screens to discover effective combinations that could act synergistically. From the MIPE-3 library of compounds we identified various enhancers of immunotoxin action and at least one major class of inhibitor. Follow-up experiments confirmed the screening data and suggested that immunotoxins when administered with everolimus or nilotinib exhibit favorable combinatory activity and would be candidates for preclinical development. Mechanistic studies revealed that everolimus-immunotoxin combinations acted synergistically on elements of the protein synthetic machinery, including S61 kinase and 4E-BP1 of the mTORC1 pathway. Conversely, PARP inhibitors antagonized immunotoxins and also blocked the toxicity due to native ADP-ribosylating toxins. Thus, our goal of investigating a chemical library was justified based on the identification of several approved compounds that could be developed preclinically as ‘enhancers’ and at least one class of mitigator to be avoided." @default.
• W2509042913 created "2016-09-16" @default.
• W2509042913 creator A5002699549 @default.
• W2509042913 creator A5009385271 @default.
• W2509042913 creator A5010769602 @default.
• W2509042913 creator A5011505146 @default.
• W2509042913 creator A5012711159 @default.
• W2509042913 creator A5014278257 @default.
• W2509042913 creator A5018575024 @default.
• W2509042913 creator A5029352038 @default.
• W2509042913 creator A5048112779 @default.
• W2509042913 creator A5056573254 @default.
• W2509042913 creator A5069062997 @default.
• W2509042913 creator A5088331887 @default.
• W2509042913 date "2016-08-24" @default.
• W2509042913 modified "2023-10-01" @default.
• W2509042913 title "Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins" @default.
• W2509042913 cites W1503438909 @default.
• W2509042913 cites W1971451473 @default.
• W2509042913 cites W1973288871 @default.
• W2509042913 cites W1979113130 @default.
• W2509042913 cites W1979819215 @default.
• W2509042913 cites W1982345327 @default.
• W2509042913 cites W1986139301 @default.
• W2509042913 cites W2009013652 @default.
• W2509042913 cites W2011366619 @default.
• W2509042913 cites W2012133321 @default.
• W2509042913 cites W2043228552 @default.
• W2509042913 cites W2074162426 @default.
• W2509042913 cites W2078094559 @default.
• W2509042913 cites W2079012552 @default.
• W2509042913 cites W2086286404 @default.
• W2509042913 cites W2094447499 @default.
• W2509042913 cites W2101371847 @default.
• W2509042913 cites W2106443011 @default.
• W2509042913 cites W2106731734 @default.
• W2509042913 cites W2114640540 @default.
• W2509042913 cites W2115543909 @default.
• W2509042913 cites W2120104555 @default.
• W2509042913 cites W2120656656 @default.
• W2509042913 cites W2122828730 @default.
• W2509042913 cites W2134106182 @default.
• W2509042913 cites W2139519346 @default.
• W2509042913 cites W2143939343 @default.
• W2509042913 cites W2144771876 @default.
• W2509042913 cites W2150836754 @default.
• W2509042913 cites W2153375051 @default.
• W2509042913 cites W2156671071 @default.
• W2509042913 cites W2166710464 @default.
• W2509042913 cites W2221202626 @default.
• W2509042913 cites W2312282875 @default.
• W2509042913 cites W2338868660 @default.
• W2509042913 cites W2343699063 @default.
• W2509042913 cites W2409988321 @default.
• W2509042913 cites W4240354991 @default.
• W2509042913 cites W636925189 @default.
• W2509042913 doi "https://doi.org/10.1371/journal.pone.0161415" @default.
• W2509042913 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4996465" @default.
• W2509042913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27556570" @default.
• W2509042913 hasPublicationYear "2016" @default.
• W2509042913 type Work @default.
• W2509042913 sameAs 2509042913 @default.
• W2509042913 citedByCount "8" @default.
• W2509042913 countsByYear W25090429132017 @default.
• W2509042913 countsByYear W25090429132018 @default.
• W2509042913 countsByYear W25090429132020 @default.
• W2509042913 countsByYear W25090429132022 @default.
• W2509042913 countsByYear W25090429132023 @default.
• W2509042913 crossrefType "journal-article" @default.
• W2509042913 hasAuthorship W2509042913A5002699549 @default.
• W2509042913 hasAuthorship W2509042913A5009385271 @default.
• W2509042913 hasAuthorship W2509042913A5010769602 @default.
• W2509042913 hasAuthorship W2509042913A5011505146 @default.
• W2509042913 hasAuthorship W2509042913A5012711159 @default.
• W2509042913 hasAuthorship W2509042913A5014278257 @default.
• W2509042913 hasAuthorship W2509042913A5018575024 @default.
• W2509042913 hasAuthorship W2509042913A5029352038 @default.
• W2509042913 hasAuthorship W2509042913A5048112779 @default.
• W2509042913 hasAuthorship W2509042913A5056573254 @default.
• W2509042913 hasAuthorship W2509042913A5069062997 @default.
• W2509042913 hasAuthorship W2509042913A5088331887 @default.
• W2509042913 hasBestOaLocation W25090429131 @default.
• W2509042913 hasConcept C104317684 @default.
• W2509042913 hasConcept C109316439 @default.
• W2509042913 hasConcept C115085202 @default.
• W2509042913 hasConcept C123894998 @default.
• W2509042913 hasConcept C159654299 @default.
• W2509042913 hasConcept C182179738 @default.
• W2509042913 hasConcept C185592680 @default.
• W2509042913 hasConcept C202751555 @default.
• W2509042913 hasConcept C203014093 @default.
• W2509042913 hasConcept C40767141 @default.
• W2509042913 hasConcept C502942594 @default.
• W2509042913 hasConcept C542903549 @default.
• W2509042913 hasConcept C55493867 @default.
• W2509042913 hasConcept C86803240 @default.
• W2509042913 hasConcept C98274493 @default.
• W2509042913 hasConceptScore W2509042913C104317684 @default.

• next